The U.S. Food and Drug Administration (FDA) has approved the use of a self-expanding transcatheter aortic valve replacement (TAVR) platform on patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

New research shows that women who have high-risk pregnancies or complications with childbirth are up to eight times more likely to develop heart disease later in their lives, but most mothers and doctors aren’t aware of it, reports NPR.

It’s logical that frailty factors into recovery from major heart surgery. But what, exactly, is the best method for judging a patient’s frailty before transcatheter or surgical aortic valve replacement (TAVR/SAVR)? A study published online July 7 in the Journal of the American College of Cardiology explored this question by examining seven frailty scales in predicting poor outcomes.

New research published this week adds to existing evidence that there’s an association between high body mass index (BMI) and an increased risk of cardiometabolic diseases like hypertension, coronary heart disease and type 2 diabetes.

New research suggests that certain times of year or days of the week could have an effect on the incidence of myocardial infarction (MI).

In a new health policy statement, the U.S. Food and Drug Administration (FDA) and other major health organizations have called for improvements in the way medications are developed and tested in children with heart disease.

IRVINE, Calif., July 5, 2017 – Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it received U.S. Food and Drug Administration (FDA) approval for its INSPIRIS RESILIA aortic valve, the first in a new class of resilient heart valves.

New manufacturing methods can further personalize medicine—and now 3D printing may offer cardiologists a method of testing transcatheter aortic valve replacements (TAVR) for leakage before implantation.